Shares of the biotech firm Geron Corporation (NASDAQ:GERN) move up subsequent to Stifel Nicolas starting it off with a Buy and a price target of $4. Earlier in August a SA article reported that Geron’s drugs “have the potential to change the way cancer is treated.” The rating now contributes to the positive chatter surrounding the firm.
Investing Insights: Is Facebook’s Stock a Buy Before Labor Day?
Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals division resolves a dispute with 36 states plus the District of Columbia based upon allegations linked to promotional and marketing practices for its anti-psychotic medication Risperdal. Through the terms, Janssen will pay around $181 million, with pro-rated portions to be paid to each state participating in the settlement.
St. Jude Medical, Inc. (NYSE:STJ) reports plans for restructuring, as it intends to realign its product units into two new operating entities, namely, an Implantable Electronic Systems Division and a Cardiovascular and Ablation Technologies Division. Further, the company will centralize several support functions including information tech, human resources, legal, business development, and various marketing functions.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.